Lenvima

Lenvima is the brand name for lenvatinib, a targeted therapy medication used to treat certain types of cancer. It is an oral tyrosine kinase inhibitor, meaning it works by blocking specific enzymes that cancer cells need to grow and divide. Lenvima is primarily used in combination with other drugs to treat advanced or metastatic thyroid cancer that has not responded to radioactive iodine treatment. It is also used in combination with other therapies for advanced renal cell carcinoma (kidney cancer) and unresectable hepatocellular carcinoma (liver cancer).

The mechanism of action of Lenvima involves inhibiting multiple receptor tyrosine kinases, including those for vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), and RET proto-oncogene. By blocking these pathways, Lenvima interferes with tumor angiogenesis (the formation of new blood vessels that feed the tumor) and tumor cell proliferation.

Common side effects of Lenvima can include fatigue, diarrhea, hypertension (high blood pressure), decreased appetite, weight loss, and nausea. More serious side effects may involve cardiac issues, liver problems, and kidney problems. Due to its potential side effects, Lenvima is typically administered under the close supervision of a healthcare professional experienced in cancer treatment. The dosage and duration of treatment are determined by the specific type and stage of cancer, as well as the individual patient's response and tolerance to the medication.